middle.news
Radiopharm Theranostics Doses First Patient in Pioneering HER2-Targeted Trial
8:36am on Wednesday 4th of June, 2025 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Doses First Patient in Pioneering HER2-Targeted Trial
8:36am on Wednesday 4th of June, 2025 AEST
Key Points
First patient dosed in Phase 1 HEAT trial of 177Lu-RAD202
Trial focuses on safety, tolerability, and dose optimization for HER2-positive cancers
RAD202 is a proprietary nanobody targeting HER2 in multiple solid tumors
Previous diagnostic studies demonstrated safety and biodistribution of RAD202
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE